comparemela.com

Latest Breaking News On - Heterodimer protein - Page 1 : comparemela.com

Sino Biological's cutting-edge recombinant cytokines for research and therapeutics : Get Quote, RFQ, Price or Buy

Sino Biological's cutting-edge recombinant cytokines for research and therapeutics : Get Quote, RFQ, Price or Buy
news-medical.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from news-medical.net Daily Mail and Mail on Sunday newspapers.

United-states
China
Chinese
American
Sino-biological-us-inc
Sino-biological
American-pharmacopoeia
Image-credit
His-tag
Heterodimer-protein

Targets for bispecific antibodies : Get Quote, RFQ, Price or Buy

Bispecific antibodies are fast becoming a hot topic for research and development. ACROBiosystems offer a variety of protein targets for bispecific antibody research.

Heterodimer-protein
Flag-tag
Tag-free
His-tag-free
His-tag-flag
Llama-fc-tag
Heterodimer-coupled-magnetic
Image-credit
Bispecific-antibodies

Fc receptor proteins for research and development : Get Quote, RFQ, Price or Buy

High-quality Fc receptor proteins are crucial for determining the efficacy of antibodies. ACROBiosystems roster of Fc receptors provides the ultimate in terms of verification and purity.

His-tag
Image-credit
Heterodimer-protein
His-tag-strep
Fortebio-octet-red
Avi-tag
Fcrn-protein
Human-fcrn
His-tag-twin-strep
Mouse-fcrn
Rat-fcrn

Antigens and Fc receptor proteins for biosimilar drug targeting : Get Quote, RFQ, Price or Buy

As biosimilars are becoming more and more popular, the need to ensure their safety is paramount. ACROBiosystem’s range of biosimilar drug targets, mainly antigen receptor proteins and Fc receptor proteins are thus highly useful.

Coomassie
Ashanti
Ghana
Trastuzumab-herceptin
Merck-kga
Merck-kgaa
Us-department-of-health
Human-services
Drug-administration
European-medicines-agency
Human-her
His-tag

Targeting CD38/CD3 in the immunotherapy of Multiple Myeloma

Multiple myeloma is a common hematological malignancy that has its origins in plasma cells. Despite treatment becoming more sophisticated, there is still currently no cure. However, immunotherapy targeting CD38/CD3 is proving to be very promising.

Research-phase
Sponsored-content
Heterodimer-protein
His-tag-free
Tag-free
Flag-tag
His-tag
Mouse-igg
Llama-igg
Labeled-human
Human-igg

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.